Please login to the form below
armodafinil
This page shows the latest armodafinil news and features for those working in and with pharma, biotech and healthcare.
Teva halts development of Nuvigil in bipolar disorder
The Israel-based pharma company said that Nuvigil (armodafinil) failed to demonstrate it was significantly more effective than placebo during a phase III trial investigating its use as an adjunct therapy ... While this study demonstrated a numerical
Latest news
-
Teva suffers setback as Nuvigil fails late-stage trial
Nuvigil (armodafinil) did not show a significant improvement over placebo when added on to therapy with mood stabilisers or atypical antipsychotics in the study, which involved patients with major depression associated
-
Cephalon jet lag application rejected
Cephalon has dropped its bid to get its sleep disorder drug Nuvigil (armodafinil) approved as a treatment for jet lag after the marketing application was rejected by the US Food and
-
State of mind
Armodafinil (Nuvigil, Cephalon) is currently being investigated as a therapy for bipolar disorders. ... A phase II trial is currently underway to assess the efficacy of armodafinil in patients with bipolar depression.
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Account Director, Medical Education
-
Salary TBC
- Global Business Development Director – Health Education
-
excellent commission
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Medical Writer
-
Salary TBC
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Senior Medical Writer
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Account Manager / Account Director
-
Competative
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- FDA expecting boom in cell and gene therapies
- Moving annual total (MAT)
- AZ’s Sean Bohen to exit after business overhaul; report
- FDA moves into crisis mode as shutdown drags on
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
PMHub
Digitas Health
Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....
Latest intelligence
- NHS regional footprints
- What to expect from 2019...
- Not another weight-loss ad
- Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Quick links
Infographics
